These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20043031)

  • 1. Orphan products: an emerging trend in drug approvals.
    Coté T; Kelkar A; Xu K; Braun MM; Phillips MI
    Nat Rev Drug Discov; 2010 Jan; 9(1):84. PubMed ID: 20043031
    [No Abstract]   [Full Text] [Related]  

  • 2. The Orphan Drug Act Revisited.
    Thomas S; Caplan A
    JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 4. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
    Koivuniemi PJ
    Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
    [No Abstract]   [Full Text] [Related]  

  • 6. Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
    Yang YT; Chen B; Bennett CL
    J Clin Oncol; 2016 Dec; 34(36):4320-4322. PubMed ID: 27998222
    [No Abstract]   [Full Text] [Related]  

  • 7. Congress, the FDA, and the fair development of new medications for children.
    McKinney RE
    Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299
    [No Abstract]   [Full Text] [Related]  

  • 8. Abuses of FDA Regulatory Procedures - The Case of Suboxone.
    Haffajee RL; Frank RG
    N Engl J Med; 2020 Feb; 382(6):496-498. PubMed ID: 31914238
    [No Abstract]   [Full Text] [Related]  

  • 9. The future of orphan drug development.
    Woodcock J
    Clin Pharmacol Ther; 2012 Aug; 92(2):146-8. PubMed ID: 22814657
    [No Abstract]   [Full Text] [Related]  

  • 10. Adoption agents.
    Wapner J
    Sci Am; 2010 Jun; 302(6):19-20. PubMed ID: 20521471
    [No Abstract]   [Full Text] [Related]  

  • 11. Orphan Drug Designation and Exclusivity for "Same Drugs".
    Hong P; Sarpatwari A; Kesselheim AS
    J Law Med Ethics; 2019 Jun; 47(2):347-349. PubMed ID: 31298092
    [No Abstract]   [Full Text] [Related]  

  • 12. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 13. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME
    Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do investors value the FDA orphan drug designation?
    Miller KL
    Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 16. The routes to orphan drug designation--our recent experience at the FDA.
    Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
    Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
    [No Abstract]   [Full Text] [Related]  

  • 17. Should off-label drug use be off-the-table?
    Rivkees SA
    J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
    [No Abstract]   [Full Text] [Related]  

  • 18. The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface.
    Enna SJ; Williams M
    Adv Pharmacol; 2009; 57():xi-ii. PubMed ID: 19945649
    [No Abstract]   [Full Text] [Related]  

  • 19. The Orphan Drug Act: an engine of innovation? At what cost?
    Rohde DD
    Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.